232,984 IDEXX Laboratories, Inc. $IDXX Shares Sold by Curated Wealth Partners LLC

by · The Markets Daily

Curated Wealth Partners LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 99.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 948 shares of the company’s stock after selling 232,984 shares during the quarter. Curated Wealth Partners LLC’s holdings in IDEXX Laboratories were worth $495,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the 2nd quarter worth $25,000. SHP Wealth Management acquired a new position in IDEXX Laboratories during the fourth quarter worth about $26,000. Elevation Wealth Partners LLC lifted its stake in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the last quarter. Arlington Trust Co LLC grew its holdings in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in IDEXX Laboratories during the 4th quarter worth about $46,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday. Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. UBS Group lifted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $744.09.

View Our Latest Report on IDXX

IDEXX Laboratories Trading Up 2.4%

IDXX opened at $560.36 on Friday. The firm has a 50 day simple moving average of $534.22 and a 200 day simple moving average of $551.84. The company has a market cap of $44.15 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 2.92 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.80 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

Further Reading

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).